title: [Results and pharmacokinetic aspects of methotrexate therapy in high doses].
abstract: We used MTX as single drug treatment on the basis of an incremental dosage schedule, with doses increased from 250 mg/m2 to 750 mg/m2 or from 5 to 10 g, at intervals of 10 days. Moderately high MTX doses (750 mg/m2 at most) plus citrovorum factor rescue, failed to result in objective tumor regression in all of the 18 patients thus treated. High-dose MTX with CF rescue, by contrast, was found to produce partial remissions in 3 of the 19 cases treated thus far. Meticulous clinical monitoring and MTX serum level determinations are imperative for minimizing complications, if this drastic treatment regimen is employed.
mesh_terms: D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008727:Methotrexate / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D002955:Leucovorin; D008727:Methotrexate
vernacular_title: Ergebnisse und pharmakokinetische Untersuchungen bei hochdosierter Methotrexat-Therapie.